ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
04 mai 2021 16h01 HE
|
Esperion Therapeutics, Inc.
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL® (bempedoic acid) Tablets and...
Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
27 avr. 2021 08h00 HE
|
Esperion Therapeutics, Inc.
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy –– Nearly half of trial participants are women, a...
Esperion to Report First Quarter 2021 Financial Results May 4, 2021
12 avr. 2021 16h01 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on...
Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
06 avr. 2021 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
23 févr. 2021 16h01 HE
|
Esperion Therapeutics, Inc.
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic...
Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
09 févr. 2021 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial...
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
21 déc. 2020 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annual J.P....
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
16 déc. 2020 03h00 HE
|
Esperion Therapeutics, Inc.
- NILEMDO® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and...
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
15 déc. 2020 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating...
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
10 nov. 2020 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal...